Health & Fitness
Wed, May 23, 2012Tue, May 22, 2012Mon, May 21, 2012Sun, May 20, 2012Sat, May 19, 2012Fri, May 18, 2012Thu, May 17, 2012Wed, May 16, 2012Tue, May 15, 2012Mon, May 14, 2012Sun, May 13, 2012Sat, May 12, 2012Fri, May 11, 2012Thu, May 10, 2012Analyst Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Mixed Results for Drug Manufacturers
Published in Health and Fitness on Wednesday, May 16th 2012 at 5:31 GMT by Market Wire
May 16, 2012 08:25 ET
Analyst Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Mixed Results for Drug Manufacturers
JOHANNESBURG, SOUTH AFRICA--(Marketwire - May 16, 2012) - [ www.stockcall.com/ ] offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on Teva Pharmaceutical Industries Limited (
Weakness in the European markets continues to weigh on drug manufacturers but several companies still turned in impressive first quarter results. Register now at [ https://stockcall.com/development/stockcall/page.php?name=register.html ] to have free access to our reports on the Drug Manufacturers - Other industry.
[ www.stockcall.com/ ] is an online platform where investors doing their due-diligence on the Drug Manufacturers - Other industry can have easy and free access to our analyst research and opinions on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc.; all investors need to do is register for a complimentary membership at [ https://stockcall.com/development/stockcall/page.php?name=register.html ].
Teva Pharmaceutical Industries Ltd. saw impressive sales growth in its first quarter of the year and efforts to streamline its operations might lead to significant gains in the second half of the year. European sales lagged and fell 2% but the company has done an excellent job improving operating efficiency while growing sales and maintaining a steady pipeline of drugs to market. Investors looking for free research on Teva Pharmaceutical Industries Limited are welcome to sign up at [ www.stockcall.com/TEVA160512.pdf ] for our new report.
The importance of getting new drugs to market was exemplified in rival Forest Laboratories Inc. weak quarterly performance. The company saw revenues fall 7.3% as it struggled with expiring patent protection. Investors looking for complimentary research on Forest Laboratories Inc. are welcome to sign up at [ www.stockcall.com/FRX160512.pdf ] for our new report.
Moving forward, economic improvements in Europe would certainly be welcomed by the industry but growth in the coming months still looks feasible with or without a turnaround from the region. Competition and maintaining a steady pipeline of drugs to market will likely continue to be key factors for drug makers in the near term. Visit [ www.stockcall.com/ ] to see how companies in this industry have grown over the past years and how they are expected to perform in the future.
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.
